Articles tagged "Kidney transplantation"

2020 American Transplant Congress
Modelling Patient Outcomes after Listing for Deceased Donor Kidney Transplantation in the UK: A Novel Technique
M. Ibrahim¹, L. Mumford¹, R. Hogg¹, R. Johnson¹, M. Pearson², J. Forsythe³, C. Callaghan⁴
¹Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom, ²Winton Centre for Risk Evidence and Communication, Cambridge, United Kingdom, ³NHS Blood and Transplant, Bristol, United Kingdom, ⁴Renal, Guy's and St Thomas' NHS Trust, London, United Kingdom
*Purpose: Novel methods of data analysis and communication are needed to aid clinician and patient understanding of clinical outcomes. We aimed to demonstrate patient outcomes…
2020 American Transplant Congress
Successful Tacrolimus Withdrawal in Kidney Transplant Recipients Unleashes a Peripheral Blood Transcriptional and Functional Signature Resembling Exhaustion
P. Cravedi, M. Fribourg, S. Harztell, L. Anderson, P. Heeger
Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: Tacrolimus (Tac) is an effective anti-rejection drug in kidney transplant recipients (KTR), but its off-target effects make withdrawal desirable. Studies indicate that Tac can…
2020 American Transplant Congress
Benefits of Normothermia Regional Perfusion (NRP), Hypothermic Machine Perfusion (HMP) and Short Cold Ischemia Time (CIT) for Kidney Transplants with Controlled Donation after Circulatory Death (cDCD)
E. Savoye¹, C. Legeai¹, J. Branchereau², S. Gay³, S. Drouin⁴, F. Gaudez⁵, B. Veber⁶, J. Venhard⁷, G. Cheisson⁸, T. Kerforne⁹, O. Bastien¹, C. Antoine¹
¹Agence de la Biomedecine, La Plaine Saint Denis, France, ²CHU Nantes, Nantes, France, ³CH Annecy, Annecy, France, ⁴CHU Pitié Salpetriere, Paris, France, ⁵CHU Saint Louis, Paris, France, ⁶CHU Rouen, Rouen, France, ⁷CHU Tours, Tours, France, ⁸CHU Kremlin-Bicetre, Kremlin-Bicetre, France, ⁹CHU Poitiers, Poitiers, France
*Purpose: cDCD are considered as extended criteria donors with poorer kidney transplant outcomes and high delayed graft function (DGF) rate. We built a French national…
2020 American Transplant Congress
Reduced Dose Valganciclovir is Effective for CMV Prevention without Excess Breakthrough or Resistance in Kidney Transplantation
M. Luu¹, P. Klem¹, B. Crowther¹, M. Abidi², M. Miller¹, K. Schoeppler¹, S. Davis²
¹Pharmacy, University of Colorado Hospital, Aurora, CO, ²Medicine, University of Colorado, Aurora, CO
*Purpose: Reduced dose valganciclovir (VGC) (450 mg daily) may be a useful alternative to full dose VGC for cytomegalovirus (CMV) prophylaxis due to drug cost…
2020 American Transplant Congress
Migration of Passenger Leukocytes During Ex Vivo Warm Perfusion
L. Brasile¹, B. Stubenitsky²
¹Research and Development, BREONICS Inc., Watervliet, NY, ²Plastic, Reconstructive & Aesthetic Surgery, St. Antonius Hospital, Utrecht, Netherlands
*Purpose: Organ transplantation is a unique immunologic situation in which donor and recipient antigen presenting cells (APCs) are present upon reperfusion. Passenger leukocytes (PL) are…
2020 American Transplant Congress
Donor Mesenchymal Stem Cells in Combination with Co-Stimulation Blockade Prolong Allograft Survival
A. J. Matar, B. P. Lovasik, S. C. Kim, C. A. Breeden, D. A. Faber, D. V. Mathews, J. Regenold, A. Ghosh, A. Stephenson, W. H. Kitchens, A. B. Adams
Surgery and Transplantation, Emory University, Atlanta, GA
*Purpose: Co-stimulation blockade (CoB) has emerged as a promising immunosuppression strategy and potential alternative to calcineurin inhibitors in solid organ transplantation. Despite recent advancements, CoB…
2020 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Williamson¹, C. Meyers¹, S. Sethi¹, K. Lim¹, J. Choi¹, S. C. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 mediates inflammation and activation of T-cells, B-cells & plasma cells. Thus, IL-6 may represent an important target for desensitization (DES). Here we report…
2020 American Transplant Congress
Single Dose Rituximab and Anti-Thymocyte Globulin (ATG) Induction in Hypersensitized Kidney Transplant Recipients
A. X. Wang, U. Wang, S. Busque, C. R. Lenihan
Stanford University School of Medicine, Stanford, CA
*Purpose: Hypersensitized kidney transplant recipients (calculated panel reactive antibody (cPRA) ≥98%) may represent a population at high risk of posttransplant immunologic events. While access to…
2020 American Transplant Congress
A Comparison of Kidney Paired Donation Education Delivery Across 68 National Kidney Registry-Affiliated Centers
A. Waterman¹, E. H. Wood¹, O. N. Ranasinghe¹, J. L. Beaumont², S. McGuire³, K. Miller⁴, V. Chipman⁵, J. Sinacore⁶, M. Cooper⁷
¹Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, ²Terasaki Research Institute, Los Angeles, CA, ³UCLA Kidney and Pancreas Transplant Programs, Los Angeles, CA, ⁴UW Health, Madison, WI, ⁵UCSF Medical Center, San Francisco, CA, ⁶National Kidney Registry, Babylon, NY, ⁷Medstar Georgetown Transplant Institute, Washington, DC
*Purpose: To understand the kidney paired donation (KPD) educational delivery process and variation across centers affiliated with the National Kidney Registry (NKR) we surveyed transplant…
2020 American Transplant Congress
Utilization of Hepatitis C Positive Organs in Kidney Transplantation
J. Mandel, U. Kaszubski, A. Freeman, L. Hutchinson, M. Janusek, C. Reuter, C. Velasco, B. Wise, S. Anders, E. Bugeaud
Ochsner Medical Center, New Orleans, LA
*Purpose: The efficacy of direct acting antivirals (DAAs) in HCV has cleared the path for the use of HCV positive donor kidneys into negative recipients.…